FindTrial
Sign In

rasagiline mesylate

DRUG11 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc., Teva Neuroscience, Inc.

Conditions

Multiple System AtrophyParkinson's Disease

Phase 2

Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)
CompletedNCT00977665
Teva Branded Pharmaceutical Products R&D, Inc.Multiple System Atrophy
Start: 2009-12-31End: 2011-10-31Updated: 2015-02-26

Phase 3

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
CompletedNCT00203164
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2002-05-31End: 2006-09-30Updated: 2010-03-09
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
CompletedNCT00203034
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2000-05-31End: 2003-01-31Updated: 2010-03-09
Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
CompletedNCT00203177
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2001-10-31Updated: 2010-03-09
A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
CompletedNCT00203125
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2000-10-31End: 2003-01-31Updated: 2011-04-12
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
CompletedNCT00203060
Teva Neuroscience, Inc.Parkinson's Disease
Start: 1997-07-31End: 2000-07-31Updated: 2011-04-12
Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease
CompletedNCT00203138
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2004-06-30End: 2006-12-31Updated: 2011-04-12
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
CompletedNCT00256204
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2005-11-30End: 2009-06-30Updated: 2012-01-12

Phase 4

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
CompletedNCT00399477
Teva Neuroscience, Inc.Parkinson's Disease
Start: 2006-10-31End: 2007-07-31Updated: 2011-04-12

Unknown Phase

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
CompletedNCT00936676
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2009-07-31End: 2013-03-31Updated: 2016-04-11
Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease
CompletedNCT01032486
Teva Branded Pharmaceutical Products R&D, Inc.Parkinson's Disease
Start: 2009-12-31End: 2011-07-31Updated: 2013-08-28

Related Papers

Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study
Brain2016-05-1361 citations
Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial.
2014-12-0873 citations
Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study
JAMA Neurology2014-11-24104 citations
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
2011-04-07153 citations
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
2009-09-01548 citations